Year Founded
2001
Ownership
Public
Employees
~50
Therapeutic Areas
Oncology
Stage
Phase 2
Modalities
Bispecific antibodyAntibody-based immunotherapy

Alligator Bioscience General Information

Lead asset mitazalimab in Phase 2 for pancreatic cancer showing promising efficacy in combination with mFOLFIRINOX. Multiple other antibody programs in clinical and preclinical development.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Lund,
Sweden

Drug Pipeline

mitazalimab
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Alligator Bioscience's pipeline data

Book a demo

Key Partnerships

Orion Corporation, Aptevo Therapeutics, Shanghai Henlius Biotech, MacroGenics, BioArctic

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Alligator Bioscience Funding

Deal TypeDateAmountStatusStage
Later Stage VCMay 29, 2007$7.4MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Alligator Bioscience's complete valuation and funding history, request access »

Alligator Bioscience Licensing Deals

AssetLicenseeDateTherapeutic Area
ALG.APV-527AptevoJul 1, 2017Oncology
You're viewing 1 of 1 licensing deals. Get the full list »

Alligator Bioscience Investors

Allegro Investment, Inc. (14.4%)
Investor Type: Venture Capital
Holding: Minority
Magnus Petersson (1.338%)
Investor Type: Venture Capital
Holding: Minority
Johan Zetterstedt (0.7827%)
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »